PARP1 and ovarian carcinoma: As resistance to platinum-based chemotherapy is a strong predictor of PARP inhibitor resistance35, we examined the cytotoxic effects of a PARP inhibitor (talazoparib) and a platinum compound (cisplatin) in BRCA–wild-type (WT) ovarian cancer cells.